Global Macular Degeneration Treatment Market | Competitive Strategies And Forecasts To 2033 | Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG

Overview and Scope
Macula refers to the central portion of the retina, a light-sensitive layer of tissue at the back of the eye. The macula is responsible for central vision. Degeneration of the macula, which affects the central part of the retina (the macula) and results in distortion or loss of central vision, occurs most commonly after the age of 60 and is referred to as age-related macular generation (AMD). The macular degeneration treatment is used to treat macular degeneration eye disease and slow the disease and prevent severe loss of vision.

Sizing and Forecast
The macular degeneration treatment market size has grown rapidly in recent years. It will grow from $9.74 billion in 2023 to $10.99 billion in 2024 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to aging population, lifestyle changes, limited treatment options, rising awareness, healthcare infrastructure development.

The macular degeneration treatment market size is expected to see rapid growth in the next few years. It will grow to $16.99 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to advancements in research, increased healthcare expenditure, rising incidence rates, personalized medicine approaches, global efforts for vision health. Major trends in the forecast period include focus on neuroprotection and regeneration therapies, expansion of telemedicine and remote monitoring, personalized medicine approaches, investigation of stem cell therapies, patient-focused initiatives for awareness and education.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

Segmentation & Regional Insights
The macular degeneration treatment market covered in this report is segmented –

1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD
2) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals
3) By Route of Administration: Oral, Injectable, Other Route of Administration
4) By Types: Wet Macular Degeneration, Dry Macular Degeneration

North America was the largest region in the macular degeneration treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment market market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp

Major Driver Impacting Market Growth
The increasing burden of retinal disorders is expected to propel the growth of the macular degeneration treatment market. Retinal disorders affect the vital tissue and affect the way individuals process visual information, leading to distorted or absent vision. According to the American Academy of Ophthalmology, in 2050, an estimated 7.32 million people in the United States will have primary open-angle glaucoma, a general term used to describe a group of eye disorders, with the highest numbers among populations aged 70 to 79 years (32%), women (50%), and Hispanics (50%). The largest demographic group is Hispanic men. Therefore, the increasing burden of retinal disorders is driving the growth of the macular degeneration treatment market.

Key Industry Players
Major companies operating in the macular degeneration treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Panoptica, Nidec Pharma Inc., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Valeant Pharmaceuticals, Arrys Therapeutics Inc., Santen Pharmaceuticals, StemCells Inc., Aerie Pharmaceuticals Inc., BioXcel Therapeutics Inc., Regenxbio Inc., Spark Therapeutics Inc., Alimera Sciences Inc., Rxi Pharmaceuticals, Avita Therapeutics Ltd., Applied Genetic Technologies Corp (AGTC), Cell Medica Ltd., Ophthotech Corporation, Adverum Biotechnologies Inc., Neurotech Pharmaceuticals Inc., 4D Molecular Therapeutics Inc., GenSight Biologics Inc., NanOcular Ltd., Codiak BioSciences Inc., Nightstar Therapeutics plc

The macular degeneration treatment market report table of contents includes:

Table of Contents
1. Executive Summary
2. Urology Supplements Market Report Structure
3. Urology Supplements Market Trends And Strategies
4. Urology Supplements Market – Macro Economic Scenario
5. Urology Supplements Market Size And Growth
…..
27. Urology Supplements Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model